临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2014年
7期
1286-1287,1288
,共3页
肺腺癌%EML4-ALK%胸腔积液%实时荧光定量PCR
肺腺癌%EML4-ALK%胸腔積液%實時熒光定量PCR
폐선암%EML4-ALK%흉강적액%실시형광정량PCR
lung adenocarcinoma%EML4-ALK%pleural fluid%FQ-PCR
目的：探讨应用实时荧光定量PCR( FQ-PCR)方法检测原发性肺腺癌患者恶性胸腔积液中的EML4-ALK融合基因突变情况,并对指导克唑替尼治疗的可行性进行探讨。方法收集39例原发性肺腺癌患者的胸腔积液,使用FQ-PCR法检测EML4-ALK融合基因的阳性率。结果胸腔积液中EML4-ALK融合基因的阳性率为12.8%,克唑替尼治疗对于EML4-ALK融合基因的和无EML4-ALK融合基因的患者相比有较高的疾病控制率(80% vs 16.7%,P<0.05)。结论对难以获得组织标本的肺癌患者可选用FQ-PCR法检测肺癌患者恶性胸腔积液中EML4-ALK以指导克唑替尼的应用。
目的：探討應用實時熒光定量PCR( FQ-PCR)方法檢測原髮性肺腺癌患者噁性胸腔積液中的EML4-ALK融閤基因突變情況,併對指導剋唑替尼治療的可行性進行探討。方法收集39例原髮性肺腺癌患者的胸腔積液,使用FQ-PCR法檢測EML4-ALK融閤基因的暘性率。結果胸腔積液中EML4-ALK融閤基因的暘性率為12.8%,剋唑替尼治療對于EML4-ALK融閤基因的和無EML4-ALK融閤基因的患者相比有較高的疾病控製率(80% vs 16.7%,P<0.05)。結論對難以穫得組織標本的肺癌患者可選用FQ-PCR法檢測肺癌患者噁性胸腔積液中EML4-ALK以指導剋唑替尼的應用。
목적：탐토응용실시형광정량PCR( FQ-PCR)방법검측원발성폐선암환자악성흉강적액중적EML4-ALK융합기인돌변정황,병대지도극서체니치료적가행성진행탐토。방법수집39례원발성폐선암환자적흉강적액,사용FQ-PCR법검측EML4-ALK융합기인적양성솔。결과흉강적액중EML4-ALK융합기인적양성솔위12.8%,극서체니치료대우EML4-ALK융합기인적화무EML4-ALK융합기인적환자상비유교고적질병공제솔(80% vs 16.7%,P<0.05)。결론대난이획득조직표본적폐암환자가선용FQ-PCR법검측폐암환자악성흉강적액중EML4-ALK이지도극서체니적응용。
Objective To explore the clinical significance of FQ-PCR to detect EML4-ALK fusion gene in pleural effusion fluid of patients with lung adenocarcinoma. Methods 39 cases of MPE were collected. The mutation of EML4-ALK fusion gene was detected with FQ-PCR. Results There were 5 cases (12. 8%) with EML4-ALK fu-sion gene. Lung adenocarcinoma with EML4-ALK fusion gene had a higher disease control rate than those without mutation (80% vs 16. 7%, P<0. 05). Conclusion It is helpful to use FQ-PCR to detect EML4-AL in pleural ef-fusion fluid for patients with lung adenocarcinoma who have lost the opportunity to detect the gene mutation.
